Empyrean Capital Partners’s AbbVie ABBV Stock Holding History

Empyrean Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-800,000	Closed	-$47.4M	–	85
2015 Q4	$47.4M	Sell	800,000 -100,000	-11%	-$5.76M	1.75%	20
2015 Q3	$49M	Buy	+900,000	New	+$58.6M	2.41%	17
2015 Q2	–	Sell	-950,000	Closed	-$55.6M	–	60
2015 Q1	$55.6M	Buy	+950,000	New	+$57.4M	2.77%	13
2014 Q4	–	Sell	-1,337,600	Closed	-$77.3M	–	51
2014 Q3	$77.3M	Buy	+1,337,600	New	+$74.3M	2.73%	10

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Empyrean Capital Partners's ABBV Position: Q1 2016 in Review

Empyrean Capital Partners sold out of AbbVie (ABBV) in Q1 2016, closing a stake of 800,000 shares — an estimated $47.4M sold.

Empyrean Capital Partners first reported a position in ABBV in Q3 2014 and held it in 4 quarters. The position peaked at $77.3M in Q3 2014. 1,639 funds tracked by Wall St. Rank hold ABBV as of Q1 2016.

Empyrean Capital Partners reported no remaining AbbVie position as of Q1 2016 after selling out during the quarter.
Empyrean Capital Partners sold 800,000 AbbVie shares in Q1 2016, an estimated $47.4M.
Empyrean Capital Partners first reported a position in AbbVie in Q3 2014 and held it in 4 quarters.
Empyrean Capital Partners's AbbVie position peaked at $77.3M in Q3 2014.
1,639 funds tracked by Wall St. Rank held AbbVie as of Q1 2016.

Based on Empyrean Capital Partners's 13F filing for Q1 2016, filed 16 May 2016.